Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1404057 | 0.79 | KDM4E (0.35) | KDM4EHTTKMT2AALDH1A1 | |
| SCHEMBL16416035 | 0.79 | KDM4E (0.35) | KDM4EHTTKMT2A | |
| SCHEMBL16793357 | 0.79 | KDM4E (0.40) | KDM4EHTTKMT2A | |
| SCHEMBL16793394 | 0.79 | KDM4E (0.35) | KDM4EHTTKMT2A | |
| Hydrochloric Acid SCHEMBL20569582 | 0.77 | KDM4E (0.39) | KDM4EHTTKMT2A | |
| SCHEMBL18015406 | 0.77 | NPC1 (0.38) | KDM4EGBA1ALDH1A1 | |
| SCHEMBL17654238 | 0.75 | KDM4E (0.33) | KDM4EGBA1 | |
| SCHEMBL18612517 | 0.75 | GBA1 (0.35) | KDM4EGBA1 | |
| SCHEMBL7604249 | 0.74 | APLNR (0.41) | — | |
| SCHEMBL1169515 | 0.74 | HTT (0.35) | KDM4EHTTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0117883-B1 | PREPARATION OF 2-T-BUTYL-5-HYDROXYPYRIMIDINE BY HYDROLYSIS OF 2-T-BUTYL-5--BROMO/CHLOROPYRIMIDINE | THE DOW CHEMICAL COMPANY (US) | 1987-01-28 | — | — | EP | claimed |
| US-4474958-A | 2-Alkyl-5-halopyrimidines | THE DOW CHEMICAL COMPANY (US) | 1984-10-02 | — | — | US | claimed |
| EP-0117883-A1 | Preparation of 2-t-butyl-5-hydroxypyrimidine by hydrolysis of 2-t-butyl-5--bromo/chloropyrimidine | THE DOW CHEMICAL COMPANY (US) | 1984-09-12 | — | — | EP | claimed |
| EP-0097451-A1 | 2-Alkyl-5-pyrimidines | THE DOW CHEMICAL COMPANY (US) | 1984-01-04 | — | — | EP | claimed |
| US-4379930-A | CATALYTIC HYDROLYSIS OF 2-T-BUTYL-5-PYRIMIDINE USING DIBUTYL DISULFIDE, ELEMENTAL SULFUR AND 2-PICOLINE-N-OXIDE AS CATALYST SYSTEM | THE DOW CHEMICAL COMPANY (US) | 1983-04-12 | — | — | US | claimed |
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYSOWAY THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-3351533-B1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| CN-119677737-A | Heteroaryl compounds for the treatment of pain | 沃泰克斯药物股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119546580-A | Heteroaryl compounds for the treatment of pain | 沃泰克斯药物股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-4661488-A | Pyrimidine substituted-2,2-dimethylcyclopropane carboxylates useful for combating insect and acarine pests at a locus | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-04-28 | — | — | US | disclosed |
| EP-0117883-B1 | PREPARATION OF 2-T-BUTYL-5-HYDROXYPYRIMIDINE BY HYDROLYSIS OF 2-T-BUTYL-5--BROMO/CHLOROPYRIMIDINE | THE DOW CHEMICAL COMPANY (US) | 1987-01-28 | — | — | EP | disclosed |
| EP-0162538-A2 | Cyclopropane derivates | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-11-27 | — | — | EP | disclosed |
| EP-0139477-A2 | Process for preparing 5-substituted pyrimidines | ELI LILLY AND COMPANY (US) | 1985-05-02 | — | — | EP | disclosed |
| US-4474958-A | 2-Alkyl-5-halopyrimidines | THE DOW CHEMICAL COMPANY (US) | 1984-10-02 | — | — | US | disclosed |
| EP-0117883-A1 | Preparation of 2-t-butyl-5-hydroxypyrimidine by hydrolysis of 2-t-butyl-5--bromo/chloropyrimidine | THE DOW CHEMICAL COMPANY (US) | 1984-09-12 | — | — | EP | disclosed |
| EP-0097451-A1 | 2-Alkyl-5-pyrimidines | THE DOW CHEMICAL COMPANY (US) | 1984-01-04 | — | — | EP | disclosed |
| US-4379930-A | CATALYTIC HYDROLYSIS OF 2-T-BUTYL-5-PYRIMIDINE USING DIBUTYL DISULFIDE, ELEMENTAL SULFUR AND 2-PICOLINE-N-OXIDE AS CATALYST SYSTEM | THE DOW CHEMICAL COMPANY (US) | 1983-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388543-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN8A, SCN1B, SCN3A | KDM4E 4442/4885HTT 2180/4885KMT2A 3307/4885 |
| US-12503439-B2 | Heteroaryl compounds for the treatment of pain | TRPV1, SCN3A, KCNN3 | KDM4E 4346/4885HTT 348/4885KMT2A 3649/4885 |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | KDM4E 1748/4885HTT 4827/4885KMT2A 2566/4885 |
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | STOML2, ATP2A3, ATP2A1 | KDM4E 3136/4885HTT 866/4885KMT2A 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.